Published in Vaccine Weekly, May 24th, 2000
"Our group has recently demonstrated that the transduction of the IFN(alpha)1 gene into mouse tumor cells results in loss of tumorigenicity and development of tumor specific T-cell-mediated immunity, even when tumors resistant to the exogenous IFN treatment are used," said Maria Ferrantini and colleagues from the Istituto Superiore di Sanita and the Istituto Nazionale Tumori, Italy.
Ferrantini et al. presented data from their study at the conference Cellular Immunity and Immunotherapy of Cancer, held in Santa Fe, New Mexico. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly